JP6591392B2 - Ｉｌ−６に結合するアプタマー及びｉｌ−６介在性状態の治療または診断におけるそれらの使用 - Google Patents
Ｉｌ−６に結合するアプタマー及びｉｌ−６介在性状態の治療または診断におけるそれらの使用 Download PDFInfo
- Publication number
- JP6591392B2 JP6591392B2 JP2016501598A JP2016501598A JP6591392B2 JP 6591392 B2 JP6591392 B2 JP 6591392B2 JP 2016501598 A JP2016501598 A JP 2016501598A JP 2016501598 A JP2016501598 A JP 2016501598A JP 6591392 B2 JP6591392 B2 JP 6591392B2
- Authority
- JP
- Japan
- Prior art keywords
- aptamer
- seq
- disease
- deoxyuridine
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361782938P | 2013-03-14 | 2013-03-14 | |
| US61/782,938 | 2013-03-14 | ||
| US201361789244P | 2013-03-15 | 2013-03-15 | |
| US61/789,244 | 2013-03-15 | ||
| PCT/US2014/024669 WO2014159669A2 (en) | 2013-03-14 | 2014-03-12 | Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016517273A JP2016517273A (ja) | 2016-06-16 |
| JP2016517273A5 JP2016517273A5 (enExample) | 2017-03-16 |
| JP6591392B2 true JP6591392B2 (ja) | 2019-10-16 |
Family
ID=51625609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501598A Active JP6591392B2 (ja) | 2013-03-14 | 2014-03-12 | Ｉｌ−６に結合するアプタマー及びｉｌ−６介在性状態の治療または診断におけるそれらの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9206429B2 (enExample) |
| EP (1) | EP2970979B1 (enExample) |
| JP (1) | JP6591392B2 (enExample) |
| KR (1) | KR102242874B1 (enExample) |
| CN (3) | CN112961860A (enExample) |
| AU (1) | AU2014244534B2 (enExample) |
| CA (1) | CA2902186C (enExample) |
| ES (1) | ES2710723T3 (enExample) |
| SG (1) | SG11201507335QA (enExample) |
| WO (1) | WO2014159669A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104561013A (zh) * | 2015-01-05 | 2015-04-29 | 中国人民解放军南京军区福州总医院 | 基于高通量测序技术进行核酸适配体序列优化的方法 |
| CN105891486A (zh) * | 2015-11-15 | 2016-08-24 | 陈博 | 一种口腔癌特异性检测的试剂盒 |
| CN109312346B (zh) * | 2016-07-01 | 2024-07-30 | 私募蛋白质体操作有限公司 | 包含修饰核苷的寡核苷酸 |
| CN107663220B (zh) * | 2016-07-27 | 2020-10-02 | 上海伯豪医学检验所有限公司 | 修饰碱基、包含修饰碱基的核酸、适配体及其应用 |
| WO2018079864A1 (ko) * | 2016-10-24 | 2018-05-03 | 김성천 | TNF-α 결합 압타머 및 그것의 치료적 용도 |
| CN107238712B (zh) * | 2017-06-05 | 2018-12-28 | 中国人民解放军沈阳军区总医院 | 血浆s100a12在st段抬高型心肌梗死预后中的应用 |
| AU2019352635B2 (en) | 2018-10-02 | 2024-12-19 | WearOptimo Pty Ltd | Actuator system |
| JP7379505B2 (ja) | 2018-10-02 | 2023-11-14 | ウェアオプティモ ピーティーワイ リミテッド | 流体レベルの判定 |
| US11649460B2 (en) | 2020-03-20 | 2023-05-16 | Joao Francisco Peinado Pereira | DNA aptamers, method for inhibiting human galectin-1 and method of treating a mammal in need thereof |
| CN115851742B (zh) * | 2022-10-28 | 2025-10-10 | 合肥工业大学 | 一种IL-6/sIL-6R双特异性环状核酸适配体及试剂盒与应用 |
| KR20250168544A (ko) * | 2023-04-26 | 2025-12-02 | 유러스 세러퓨틱스 가부시키가이샤 | 표적 뉴클레오티드 서열의 개변을 위한 비천연형 폴리뉴클레오티드 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070166741A1 (en) | 1998-12-14 | 2007-07-19 | Somalogic, Incorporated | Multiplexed analyses of test samples |
| EP1667729A4 (en) | 2003-05-23 | 2007-10-17 | Univ Texas | STRUCTURAL BASED AND COMBINATORY SELECTED OLIGONUCLEOSIDE PHOSPHOROTHIOAT AND PHOSPHORODITHIOAT APTAMIC TARGETING AP-1 TRANSCRIPTION FACTORS |
| EP1756138A4 (en) | 2004-03-05 | 2009-07-01 | Archemix Corp | HUMAN CYTOKINE FAMILY BINDING APTAMERS AND THEIR USE AS THERAPEUTIC AGENTS OF AUTOIMMUNE DISEASES |
| DK1994171T3 (en) | 2006-01-17 | 2015-06-15 | Somalogic Inc | Multiplex Analyses of test samples |
| US7964356B2 (en) | 2007-01-16 | 2011-06-21 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| US7855054B2 (en) | 2007-01-16 | 2010-12-21 | Somalogic, Inc. | Multiplexed analyses of test samples |
| US8975026B2 (en) * | 2007-01-16 | 2015-03-10 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| CA2696431C (en) | 2007-07-17 | 2021-01-05 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| US20110275794A1 (en) * | 2010-04-12 | 2011-11-10 | Somalogic, Inc. | 5-position modified pyrimidines and their use |
| US8658613B2 (en) | 2010-11-30 | 2014-02-25 | Otc Biotechnologies, Llc | Methods and compositions of nucleic acid ligands for detection of clinical analytes related to human health |
| FR2978964B1 (fr) * | 2011-08-09 | 2015-02-20 | Conservatoire Nat Arts | Composition vaccinale anti-il-6 |
-
2014
- 2014-03-12 JP JP2016501598A patent/JP6591392B2/ja active Active
- 2014-03-12 KR KR1020157027953A patent/KR102242874B1/ko active Active
- 2014-03-12 CN CN202110252614.9A patent/CN112961860A/zh active Pending
- 2014-03-12 CN CN201811220016.8A patent/CN109439664B/zh active Active
- 2014-03-12 ES ES14775454T patent/ES2710723T3/es active Active
- 2014-03-12 SG SG11201507335QA patent/SG11201507335QA/en unknown
- 2014-03-12 US US14/206,814 patent/US9206429B2/en active Active
- 2014-03-12 CA CA2902186A patent/CA2902186C/en active Active
- 2014-03-12 AU AU2014244534A patent/AU2014244534B2/en not_active Ceased
- 2014-03-12 EP EP14775454.3A patent/EP2970979B1/en active Active
- 2014-03-12 CN CN201480014093.1A patent/CN105051193A/zh active Pending
- 2014-03-12 WO PCT/US2014/024669 patent/WO2014159669A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201507335QA (en) | 2015-10-29 |
| CN109439664B (zh) | 2024-03-08 |
| AU2014244534A1 (en) | 2015-09-10 |
| EP2970979A2 (en) | 2016-01-20 |
| HK1217512A1 (en) | 2017-01-13 |
| CN105051193A (zh) | 2015-11-11 |
| CA2902186A1 (en) | 2014-10-02 |
| EP2970979B1 (en) | 2018-11-21 |
| CN109439664A (zh) | 2019-03-08 |
| US9206429B2 (en) | 2015-12-08 |
| KR102242874B1 (ko) | 2021-04-21 |
| WO2014159669A3 (en) | 2014-12-04 |
| KR20150140669A (ko) | 2015-12-16 |
| CN112961860A (zh) | 2021-06-15 |
| US20140315986A1 (en) | 2014-10-23 |
| AU2014244534B2 (en) | 2020-04-30 |
| WO2014159669A2 (en) | 2014-10-02 |
| CA2902186C (en) | 2023-04-11 |
| EP2970979A4 (en) | 2016-11-09 |
| ES2710723T3 (es) | 2019-04-26 |
| JP2016517273A (ja) | 2016-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6591392B2 (ja) | Ｉｌ−６に結合するアプタマー及びｉｌ−６介在性状態の治療または診断におけるそれらの使用 | |
| US11208663B2 (en) | Post-selex modification methods | |
| AU2011223527B2 (en) | Aptamers to 4-1BB and their use in treating diseases and disorders | |
| SG184089A1 (en) | APTAMERS TO ß-NGF AND THEIR USE IN TREATING ß-NGF MEDIATED DISEASES AND DISORDERS | |
| CN102625836B (zh) | Hmgb1结合核酸分子及其用途 | |
| US20220333113A1 (en) | Nucleic Acid Compounds that Bind to Retinoic Acid-Inducible Gene I Protein | |
| US9695424B2 (en) | PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders | |
| HK1217512B (en) | Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions | |
| JPWO2014148638A1 (ja) | Ｉｌ−１７に対するアプタマー及びその使用 | |
| HK40033269A (en) | Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders | |
| HK1204014B (en) | Aptamers to pdgf and vegf and their use in treating pdgf and vegf mediated conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170206 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170206 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180206 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180501 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180703 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181106 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190201 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190402 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190619 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190903 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190918 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6591392 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |